Form 4: Black Diamond COO/GC Granted 250,000 Stock Options

Brent Hatzis-Schoch, Chief Operating Officer and General Counsel of Black Diamond Therapeutics, Inc., was granted 250,000 stock options at an exercise price of $2.57 per share.

Summary

• Brent Hatzis-Schoch, the Chief Operating Officer and General Counsel of Black Diamond Therapeutics, Inc. (BDTX), acquired 250,000 derivative securities in the form of stock options.
• The options have an exercise price of $2.57 per share.
• The transaction date for this grant was January 21, 2026.
• The options are subject to a vesting schedule: 25% will vest on January 21, 2027, with the remaining options vesting in 36 equal monthly installments thereafter, contingent on continued service.
• The expiration date for these stock options is January 20, 2036.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading plan.

Sentiment

Score: 6

Explanation: The filing reports a standard executive compensation event (stock option grant), which is generally positive as it aligns management incentives with shareholder interests, but it is not a significant market-moving announcement.

Positives

• The grant of stock options to a key executive like the COO and General Counsel aligns management's interests with those of shareholders, incentivizing long-term company performance.
• The transaction was made under a Rule 10b5-1(c) plan, which can indicate a pre-planned and transparent approach to insider transactions.

Future Outlook

The filing does not provide a future outlook for the company's financial performance or strategic direction. It solely reports an executive's stock option grant.

Industry Context

The granting of stock options to key executives is a standard practice across various industries, particularly in biotechnology and pharmaceuticals, to attract, retain, and incentivize leadership. This aligns executive compensation with shareholder value creation over the long term.

Comparison to Industry Standards

• Granting stock options as part of executive compensation is a common practice in the biotechnology sector, similar to companies like Moderna or BioNTech, to align executive incentives with company performance and shareholder returns.
• The vesting schedule, with an initial cliff and subsequent monthly installments, is a typical structure designed to encourage long-term commitment and performance from executives.

Stakeholder Impact

• Shareholders: The grant of stock options to a key executive can positively impact shareholders by aligning management's financial incentives with the company's long-term stock performance, potentially leading to increased shareholder value.
• Employees: While not directly impacting all employees, executive compensation practices can influence overall company culture and compensation strategies.

Next Steps

• The stock options will begin vesting on January 21, 2027, with subsequent monthly vesting installments over the following three years, subject to the reporting person's continued service.

Key Dates

Keywords

Black Diamond Therapeutics, BDTX, Stock Options, Executive Compensation, Brent Hatzis-Schoch, Form 4, Insider Transaction, Rule 10b5-1